Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 121.11% from the stock’s […]
More Stories
US Says ‘All Options Are on the Table’ in Emergency UN Meeting on Iran
By Kimberly Hayek The United States said on Thursday that all options remain on the table to stop Iran’s violent...
How Expanded Obamacare Made Premiums Spiral, Americans Dependent
By Lawrence Wilson and Sylvia Xu Congress responded to the COVID-19 pandemic by passing the American Rescue Plan Act in...
How Advanced Browsers Limit Digital Tracking
As the online world evolves, digital privacy is becoming increasingly important. Many users now seek options beyond standard browsers. With...
Bilt Launches 3 New Credit Cards With 10 Percent Interest Cap for First Year
By Mary Prenon Bilt, one of America’s youngest credit card firms, founded in 2019, is launching a suite of three...
Trump Unveils New Health Care Affordability Plan
By Lawrence Wilson President Donald Trump on Jan. 15 released his administration’s new health care affordability plan, which aims to...
US, Denmark, Greenland to Form Working Group to Find Agreement on Island’s Future
By Ryan Morgam and Emel Akan WASHINGTON—Following a White House meeting on Jan. 14, the foreign ministers of Denmark and...